|
¿ÍÀÌ¿¥Ä¿¸®¾î |
[ÄÚ½º´Ú»óÀå À¯¸Á ¹ÙÀÌ¿À ±â¾÷] ¾à¹°°¨½Ã(PV) ä¿ë
¼¿ï °³²±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
PL/PV/PMS/MD |
3³â¡è |
ä¿ë½Ã |
05.25 |
|
|
´õ ÈÞ¸Õ |
±¹³» À¯¸í»óÀåÁ¦¾à»ç PV ÆÀÀå±Þ Æ÷Áö¼Ç ASAP
¼¿ï Á¾·Î±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
PL/PV/PMS/MD |
3³â¡è |
ä¿ë½Ã |
05.19 |
|
|
(ÁÖ)¸¶ÀÌ´õ½º¿¡ÀÌÄ¡¾Ë |
(Á¦¾à/¹ÙÀÌ¿À) Field Application Researcher
°æ±â ¼ö¿ø½Ã ¿µÅ뱸 | Çз¹«°ü |
PL/PV/PMS/MD |
3³â¡è |
ä¿ë½Ã |
11.29 |
|
|
HRKorea |
Pharmacovigilance Specialist
¼¿ï ÀüÁö¿ª | ´ëÇÐ(4³â) Á¹¾÷ |
PL/PV/PMS/MD |
3³â¡è |
ä¿ë½Ã |
05.18 |
|
|
ÆÊÄ¿³ØÆà |
[½Å¾à°³¹ß»ç] ºñÀÓ»ó´ã´ç PL
°æ±â ¼ö¿ø½Ã ¿µÅ뱸 | ´ëÇпø(¼®»ç) Á¹¾÷ |
PL/PV/PMS/MD |
2³â¡è |
05.31 |
04.16 |
|
|
Á¦À̾ØÆÄÆ®³ÊÁîÄÚ¸®¾Æ(ÁÖ) |
[À¯¸íÁ¦¾à»ç] PV / 2³âÀÌ»ó~12³â¹Ì¸¸ /¼Ãʱٹ«
¼¿ï ¼Ãʱ¸ | ´ëÇÐ(4³â) Á¹¾÷ |
PL/PV/PMS/MD |
2³â¡è |
ä¿ë½Ã |
06.27 |
|
|
JYpartners |
[[µ¶ÀÏ°è Åõ¼® Àü¹®±â¾÷]]PV manager ½Å±Ôä¿ë
¼¿ï °³²±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
PL/PV/PMS/MD |
2³â¡è |
ä¿ë½Ã |
12.03 |
|
|
JYpartners |
[[¾à»ç, ÇѾà»ç Çʼö]] CRA 2³â ÀÌ»ó °æ·ÂÀÚ OK
¼¿ï °³²±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
PL/PV/PMS/MD |
2³â¡è |
ä¿ë½Ã |
05.06 |
|
|
ÇÁ·ÎÇÚÁîÄÚ¸®¾Æ |
»óÀåÁ¦¾à»ç PV(ÁÖÀÓ~°úÂ÷Àå±Þ)
¼¿ï ÀüÁö¿ª | ´ëÇÐ(4³â) Á¹¾÷ |
PL/PV/PMS/MD |
2³â¡è |
ä¿ë½Ã |
08.31 |
|
|
HRKorea |
°³¹ßº»ºÎ³» PVÆÀ : PV SOP/°¡À̵å¶óÀÎ µî °ü¸®¹®¼ Á¦/°³Á¤
¼¿ï ÀüÁö¿ª | ´ëÇÐ(4³â) Á¹¾÷ |
PL/PV/PMS/MD |
2³â¡è |
ä¿ë½Ã |
12.22 |
|
|
Á¦À̾ØÆÄÆ®³ÊÁîÄÚ¸®¾Æ(ÁÖ) |
[±¹³»Á¦¾à»ç] PV (2³â ÀÌ»ó)
¼¿ï ¼Ãʱ¸ | ´ëÇÐ(4³â) Á¹¾÷ |
PL/PV/PMS/MD |
2³â¡è |
ä¿ë½Ã |
07.01 |
|
|
Á¦À̾ØÆÄÆ®³ÊÁîÄÚ¸®¾Æ(ÁÖ) |
[±¹³»Á¦¾à»ç] PV (2³â ÀÌ»ó)
¼¿ï ¼Ãʱ¸ | ´ëÇÐ(4³â) Á¹¾÷ |
PL/PV/PMS/MD |
2³â¡è |
ä¿ë½Ã |
06.23 |
|
|
ÇÁ·ÎÇÚÁîÄÚ¸®¾Æ |
´ëÇüÁ¦¾à»ç PV/MI(´ë¸®~°úÀå±Þ)
°æ±â ÀüÁö¿ª | ´ëÇÐ(4³â) Á¹¾÷ |
PL/PV/PMS/MD |
2³â¡è |
ä¿ë½Ã |
05.03 |
|
|
ÆÊÄ¿³ØÆà |
[½Å¾à°³¹ß»ç] ºñÀÓ»ó´ã´ç PL
°æ±â ¼ö¿ø½Ã ¿µÅ뱸 | ´ëÇпø(¼®»ç) Á¹¾÷ |
PL/PV/PMS/MD |
2³â¡è |
05.31 |
04.02 |
|
|
Ä¿¸®¾îÄɾî |
´Ù±¹ÀûÁ¦¾àȸ»ç CSO (Clinical Safety Officer)
¼¿ï ÀüÁö¿ª | ´ëÇÐ(4³â) Á¹¾÷ |
PL/PV/PMS/MD |
2³â¡è |
ä¿ë½Ã |
09.27 |
|